Zhejiang Haichang Bio-Tech 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
2 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Mychexin (WGI-0301) / Zhejiang Haichang Bio-Tech
NCT06309485: Phase 2 Study of WGI-0301 for Advanced HCC

Not yet recruiting
2
60
NA
WGI-0301 at MTD/RP2D dose IV infusion, QW, WGI-0301 at MTD/RP2D -1 dose IV infusion, QW, Sorafenib 400 mg PO, BID continuously, Sorafenib 400 mg PO, BID
Zhejiang Haichang Biotech Co., Ltd.
Advanced Hepatocellular Carcinoma (HCC)
08/26
12/26
NCT05267899: A Phase I First in Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of WGI-0301 in Patients With Advanced Solid Tumors

Recruiting
1
24
US
WGI-0301
Zhejiang Haichang Biotech Co., Ltd.
Advanced Solid Tumors
10/24
12/24
Archexin (HC0201) / Zhejiang Haichang Bio-Tech
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Mychexin (WGI-0301) / Zhejiang Haichang Bio-Tech
NCT06309485: Phase 2 Study of WGI-0301 for Advanced HCC

Not yet recruiting
2
60
NA
WGI-0301 at MTD/RP2D dose IV infusion, QW, WGI-0301 at MTD/RP2D -1 dose IV infusion, QW, Sorafenib 400 mg PO, BID continuously, Sorafenib 400 mg PO, BID
Zhejiang Haichang Biotech Co., Ltd.
Advanced Hepatocellular Carcinoma (HCC)
08/26
12/26
NCT05267899: A Phase I First in Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of WGI-0301 in Patients With Advanced Solid Tumors

Recruiting
1
24
US
WGI-0301
Zhejiang Haichang Biotech Co., Ltd.
Advanced Solid Tumors
10/24
12/24
Archexin (HC0201) / Zhejiang Haichang Bio-Tech
No trials found

Download Options